A New Drug Design Targeting the Adenosinergic System for Huntington's Disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Huntington's disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as well as aggregate formation of mutant Htt. Effective treatments for HD are yet to be developed. METHODOLOGY/PRINCIPAL FINDINGS: Here, we report a novel dual-function compound, N(6)-(4-hydroxybenzyl)adenine riboside (designated T1-11) which activates the A(2A)R and a major adenosine transporter (ENT1). T1-11 was originally isolated from a Chinese medicinal herb. Molecular modeling analyses showed that T1-11 binds to the adenosine pockets of the A(2A)R and ENT1. Introduction of T1-11 into the striatum significantly enhanced the level of striatal adenosine as determined by a microdialysis technique, demonstrating that T1-11 inhibited adenosine uptake in vivo. A single intraperitoneal injection of T1-11 in wildtype mice, but not in A(2A)R knockout mice, increased cAMP level in the brain. Thus, T1-11 enters the brain and elevates cAMP via activation of the A(2A)R in vivo. Most importantly, addition of T1-11 (0.05 mg/ml) to the drinking water of a transgenic mouse model of HD (R6/2) ameliorated the progressive deterioration in motor coordination, reduced the formation of striatal Htt aggregates, elevated proteasome activity, and increased the level of an important neurotrophic factor (brain derived neurotrophic factor) in the brain. These results demonstrate the therapeutic potential of T1-11 for treating HD. CONCLUSIONS/SIGNIFICANCE: The dual functions of T1-11 enable T1-11 to effectively activate the adenosinergic system and subsequently delay the progression of HD. This is a novel therapeutic strategy for HD. Similar dual-function drugs aimed at a particular neurotransmitter system as proposed herein may be applicable to other neurotransmitter systems (e.g., the dopamine receptor/dopamine transporter and the serotonin receptor/serotonin transporter) and may facilitate the development of new drugs for other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
I-TASSER server for protein 3D structure prediction
Zhang, Y. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-40 · Cited by 5,124
Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges
Gasteiger, J., & Marsili, M. (1980) · Tetrahedron · doi:10.1016/0040-4020(80)80168-2 · Cited by 4,157 · cited 1×
“molecules were determined by the Gasteiger method [93], aided”
MethodMangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
A semiempirical free energy force field with charge‐based desolvation
Huey, R., Morris, G. M., Olson, A. J., & Goodsell, D. S. (2007) · Journal of Computational Chemistry · doi:10.1002/jcc.20634 · Cited by 2,246
Crystal structure of opsin in its G-protein-interacting conformation
Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauß, N., Choe, H.-W., Hofmann, K. P., & Ernst, O. P. (2008) · Nature · doi:10.1038/nature07330 · Cited by 1,059 · cited 2×
“, residues 175,310, were modeled based on the opsin structure [81].”
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Chiang, M.-C., Chen, H.-M., Lee, Y.-H., Chang, H.-H., Wu, Y.-C., Soong, B.-W., Chen, C.-M., Wu, Y.-R., Liu, C.-S., Niu, D.-M., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl481 · Cited by 95 · cited 2×
“Formation of Htt aggregates and alteration of overall gene expression profiles have also been reported in peripheral tissues, including blood cells, the liver, and the kidney [2,3].”
Self-citation
Cited by
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Self-citationManoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Lin, J.-T., Chang, W.-C., Chen, H.-M., Lai, H.-L., Chen, C.-Y., Tao, M.-H., & Chern, Y. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01434-12 · Cited by 70
Self-citationPasquini, S., Contri, C., Cappello, M., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1030895 · Cited by 29
Duarte, A. I., Sjögren, M., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Björkqvist, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27121-w · Cited by 25
Metadata
- Authors
- Huang, N.-K., Lin, J.-H., Lin, J.-T., Lin, C.-I., Liu, E. M., Lin, C.-J., Chen, W.-P., Shen, Y.-C., Chen, H.-M., Chen, J.-B., Lai, H.-L., Yang, C.-W., Chiang, M.-C., Wu, Y.-S., Chang, C., Chen, J.-F., Fang, J.-M., Lin, Y.-L., & Chern, Y.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-06-21
- Volume
- 6
- Issue
- 6
- Pages
- e20934
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2048277695
- Cited by
- 82
- References
- 7
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Drug Design Targeting the Adenosinergic System for Huntington's Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0020934
- The paper
- Huang, N.-K., Lin, J.-H., Lin, J.-T., Lin, C.-I., Liu, E. M., Lin, C.-J., Chen, W.-P., Shen, Y.-C., Chen, H.-M., Chen, J.-B., Lai, H.-L., Yang, C.-W., Chiang, M.-C., Wu, Y.-S., Chang, C., Chen, J.-F., Fang, J.-M., Lin, Y.-L., & Chern, Y. (2011). A New Drug Design Targeting the Adenosinergic System for Huntington's Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0020934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.